By Alliance for Natural Health

Even worse, it’s frequently prescribed to the most at-risk group: women in their 40s and 50s. Action Alert!

We’ve told you before about the dangers of SSRIs, an incredibly popular class of antidepressants that can cause violent outbursts—both homicidal and suicidal. But now, researchers have found another alarming side effect: they may promote breast cancer.

About 70% of breast cancers are sensitive to estrogen—that is, estrogen contributes to their growth. Recently, researchers have found that paroxetine—the active ingredient in Paxil and Pexeva, some of the most widely prescribed SSRI antidepressants—has an estrogenic effect that likely promotes the development and growth of breast tumors in women.

The same study also identified bisphenol A, or BPA, which we have also warned about, as having estrogenic effects. BPA is found in some plastics, and in particular in the liner of tin cans and on many sales receipts.

In thinking about the breast cancer risk from SSRIs, keep in mind that clinical depression is twice as common in women as it is in men. In fact, one in four women in their 40s and 50s (one in ten Americans overall) now take an antidepressant medication.

As you may recall, last year the FDA approved paroxetine (marketed under the name Brisdelle) as a treatment for hot flashes and menopausal symptoms—despite the fact that the FDA’s own Reproductive Health Drugs Advisory Committee voted 10 to 4 against approval, because the severe side effects associated with SSRIs outweigh the minor benefits. In addition, SSRIs can be highly addictive. Many people struggle to get off them.

The agency touted its decision to approve Brisdelle as an opportunity to provide women with a non-hormonal alternative to synthetic hormone replacement therapy (a common way to treat hot flashes). Why? Because synthetic—but not bioidentical hormone—therapy has been shown to increase the risk of breast cancer as well as heart disease.

Let’s walk through this. The two most important risk factors to developing breast cancer are being female and growing older: the older you get, the more likely you are to get breast cancer. So the FDA has approved a drug that may cause breast cancer for the group most at risk for breast cancer—in the hope of reducing breast cancer.

Is there a link between increased antidepressant use and increased rates of breast cancer? There’s no way to tell without a reputable, long-term study, but it’s not far-fetched to think that these two trends are linked.

You’ll note that the FDA conveniently ignored the safer alternative treatment option for post-menopausal symptoms: natural, bioidentical estriol. In addition, as Dr. Joseph Mercola points out, there are well over 800 references in the medical literature showing vitamin D’s effectiveness against cancer. Most recently, a meta-analysis of five studies published in the March 2014 issue of Anticancer Research found that patients diagnosed with breast cancer who had high vitamin D levels were twice as likely to survive compared to women with low levels. Moreover, high levels of vitamin D in conventional medicine is not really high by integrative medicine standards. Conventional medicine considers ng/ml blood levels of 30-100 to be safe. To prevent cancer and other health hazards, there is considerable evidence that levels need to be above 60 while still below 100.

For more about breast cancer and its diagnosis, see our other article in this issue.

Action Alert! Tell the FDA to reverse its approval of paroxetine for hot flashes. There is no reason for this dangerous drug’s approval, especially considering that it does the opposite of what it was intended to do when it was initially approved—reduce the risk of breast cancer. Send your message to the FDA today!

Read the full article here: http://www.anh-usa.org/popular-antidepressant-may-promote-breast-cancer/

We Lost the War on Cancer – Review of Alternative Cancer Therapies

eBook
Retail : $9⁹⁹
Now : $5⁹⁹

We have lost the war on cancer. At the beginning of the last century, one person in twenty would get cancer. In the 1940s it was one out of every sixteen people. In the 1970s it was one person out of ten. Today one person out of three gets cancer in the course of their life.

The cancer industry is probably the most prosperous business in the United States. In 2014, there will be an estimated 1,665,540 new cancer cases diagnosed and 585,720 cancer deaths in the US. $6 billion of tax-payer funds are cycled through various federal agencies for cancer research, such as the National Cancer Institute (NCI). The NCI states that the medical costs of cancer care are $125 billion, with a projected 39 percent increase to $173 billion by 2020.

The simple fact is that the cancer industry employs too many people and produces too much income to allow a cure to be found. All of the current research on cancer drugs is based on the premise that the cancer market will grow, not shrink.

John Thomas explains to us why the current cancer industry prospers while treating cancer, but cannot afford to cure it in Part I. In Part II, he surveys the various alternative cancer therapies that have been proven effective, but that are not approved by the FDA.

Purchase the DVD – Free Shipping Available! Click image to view the trailer.